Diammonium Glycyrrhizinate Capsules Market Poised for Steady Growth to USD 67.88 Million by 2032: The Natural Compound Revolutionizing Chronic Hepatitis Management
Liver disease has emerged as one of the most pressing global health challenges of the 21st century. Chronic hepatitis B alone affects approximately 296 million people worldwide according to the World Health Organization, representing a vast patient population requiring long-term therapeutic management to prevent progression to cirrhosis and hepatocellular carcinoma. While direct-acting antiviral agents have transformed treatment paradigms, the need for hepatoprotective and immunomodulatory therapies that support liver function and inhibit disease progression remains substantial, particularly in regions where viral hepatitis prevalence is endemic and access to expensive biologic therapies remains constrained. Diammonium glycyrrhizinate capsules, derived from the natural compound glycyrrhizic acid extracted from licorice root, have established a distinctive therapeutic position in this landscape through their dual-action mechanism of inhibiting viral replication while simultaneously modulating the host immune response. This market analysis explores how this specialized hepatoprotective medication is positioned for sustained growth, driven by expanding diagnosis rates, increasing liver health awareness, and the medication’s established safety profile in long-term administration.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Diammonium Glycyrrhizinate Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Diammonium Glycyrrhizinate Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6080152/diammonium-glycyrrhizinate-capsules
Market Analysis: Understanding the Liver Protection Therapeutics Landscape
The global market for Diammonium Glycyrrhizinate Capsules was estimated to be worth USD 51.1 million in 2025 and is projected to reach USD 67.88 million, growing at a CAGR of 4.2% from 2026 to 2032. This steady growth trajectory reflects the medication’s established position within hepatoprotective drug market protocols, particularly in Asian markets where licorice-derived therapeutics have been integrated into clinical practice guidelines for decades. Diammonium Glycyrrhizinate Capsules can inhibit viral replication and modulate the host’s immune response to viral infections. This dual action makes it a valuable therapeutic option for managing chronic hepatitis and preventing disease progression. The active pharmaceutical ingredient, diammonium glycyrrhizinate, is the diammonium salt of glycyrrhizic acid—a triterpenoid saponin glycoside that constitutes the primary bioactive component of Glycyrrhiza glabra (licorice) root. Its hepatoprotective mechanism operates through multiple pathways: stabilization of hepatocyte cell membranes, scavenging of reactive oxygen species that drive hepatic inflammation, inhibition of phospholipase A2 activity, and modulation of cytokine production that influences the balance between tissue repair and fibrotic progression.
Industry Trends: Expanding Applications in Chronic Liver Disease Management
Several compelling market trends are reshaping the liver disease treatment market and expanding the addressable patient population for diammonium glycyrrhizinate therapy. The rising global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, represents a significant industry trend with profound implications for hepatoprotective medication demand. MASLD now affects an estimated 25-30% of the global adult population, creating a vast patient cohort requiring long-term liver function management. While diammonium glycyrrhizinate’s primary clinical evidence base centers on viral hepatitis, its hepatoprotective and anti-inflammatory properties have attracted increasing research attention for broader liver disease applications. The market analysis indicates that expanding clinical indications and growing physician familiarity with glycyrrhizinate-based therapies are gradually extending prescribing beyond traditional hepatitis B and C patient populations toward comprehensive liver health management.
Simultaneously, healthcare infrastructure development in emerging markets is improving hepatitis diagnosis rates and expanding access to pharmaceutical interventions. Enhanced screening programs, particularly in Asia-Pacific countries where hepatitis B prevalence has historically been among the highest globally, are identifying previously undiagnosed chronic carriers who require ongoing hepatoprotective therapy. This diagnostic improvement trend directly expands the addressable market for chronic hepatitis treatment medications including diammonium glycyrrhizinate capsules. The medication’s favorable safety profile, established through decades of clinical use in Asian medical systems, positions it as an accessible therapeutic option in healthcare systems where newer biologic agents remain cost-prohibitive.
Competitive Landscape: Generic Competition and Market Accessibility
The Diammonium Glycyrrhizinate Capsules market is segmented as below:
Chia Tai Tianqing Pharmaceutical
Suzhou Erye Pharmaceutical
China Resources Double-Crane Pharmaceutical
Shanxi Tongda Pharmaceutical
Sichuan Shenghe Pharmaceutical
Segment by Type
Original Drug
Generic Drug
Segment by Application
Hospital
Clinic
Others
The competitive landscape reflects the dynamics of a mature hepatoprotective pharmaceuticals market where multiple domestic Chinese manufacturers have established production capabilities. Chia Tai Tianqing Pharmaceutical, as a leading player in the Chinese hepatology pharmaceutical market, commands a significant diammonium glycyrrhizinate market share through its established distribution networks, physician relationships, and manufacturing scale. Suzhou Erye Pharmaceutical, China Resources Double-Crane Pharmaceutical, Shanxi Tongda Pharmaceutical, and Sichuan Shenghe Pharmaceutical represent the competitive fringe of domestic manufacturers whose generic formulations have expanded patient access through cost-competitive pricing. The segmentation between original drug and generic drug categories reflects the pharmaceutical industry’s broader intellectual property and market access dynamics: original drug formulations, supported by clinical trial data and physician familiarity, maintain premium positioning, while generic alternatives drive market expansion through affordability and formulary inclusion in cost-conscious healthcare systems.
The application segmentation between hospital and clinic settings reflects the dual prescribing environment for liver protection medication. Hospital-based gastroenterology and hepatology departments typically initiate therapy following chronic hepatitis diagnosis, managing acute exacerbations and establishing treatment protocols. Community-based clinics manage long-term maintenance prescribing, medication adherence monitoring, and liver function surveillance—a chronic disease management model essential for preventing disease progression in asymptomatic patients who may otherwise discontinue therapy.
Industry Outlook: Future Growth Catalysts and Strategic Considerations
The healthcare market outlook for diammonium glycyrrhizinate capsules remains characterized by steady, sustainable growth rather than explosive expansion—a profile that appeals to pharmaceutical portfolio managers seeking predictable, non-cyclical revenue streams. Several growth catalysts are expected to sustain the 4.2% CAGR trajectory through 2032. Increasing integration of traditional and natural medicine-derived compounds into evidence-based treatment protocols, supported by modern pharmacokinetic studies and clinical trial data, enhances physician confidence in glycyrrhizinate-based therapies. Expanding research into the medication’s anti-inflammatory and immunomodulatory mechanisms may support broader indications beyond viral hepatitis. Additionally, the medication’s oral capsule formulation provides convenient outpatient administration, supporting medication adherence in chronic conditions requiring long-term therapy.
The trajectory from USD 51.1 million to USD 67.88 million by 2032 represents measured but meaningful growth in a specialized pharmaceutical segment where clinical necessity, established safety profiles, and expanding diagnostic capabilities converge. For pharmaceutical executives, healthcare investors, and hepatology practice leaders, comprehensive market research confirms that diammonium glycyrrhizinate capsules maintain a distinctive therapeutic position within the evolving liver disease treatment landscape, offering a natural compound-derived pharmaceutical option in an era of increasing interest in plant-based therapeutics validated by modern clinical evidence.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
